Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Treasury Shares (2021 - 2025)

Historic Treasury Shares for GeneDx Holdings (WGS) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • GeneDx Holdings' Treasury Shares fell 2474.5% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 2474.5%. This contributed to the annual value of $1.9 million for FY2024, which is 2398.63% up from last year.
  • As of Q3 2025, GeneDx Holdings' Treasury Shares stood at $1.6 million, which was down 2474.5% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Treasury Shares registered a high of $23.7 million during Q3 2022, and its lowest value of $855061.0 during Q4 2022.
  • In the last 5 years, GeneDx Holdings' Treasury Shares had a median value of $1.9 million in 2023 and averaged $5.8 million.
  • In the last 5 years, GeneDx Holdings' Treasury Shares plummeted by 9320.82% in 2022 and then surged by 7634.73% in 2023.
  • Over the past 5 years, GeneDx Holdings' Treasury Shares (Quarter) stood at $12.6 million in 2021, then plummeted by 93.21% to $855061.0 in 2022, then skyrocketed by 76.35% to $1.5 million in 2023, then rose by 23.99% to $1.9 million in 2024, then dropped by 15.27% to $1.6 million in 2025.
  • Its Treasury Shares was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.8 million in Q1 2025.